Ranganath Sudhir Hulikal, Kee Irene, Krantz William B, Chow Pierce Kah-Hoe, Wang Chi-Hwa
Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore.
Pharm Res. 2009 Sep;26(9):2101-14. doi: 10.1007/s11095-009-9922-2. Epub 2009 Jun 20.
To develop paclitaxel-delivering PLGA microspheres entrapped in a gel matrix with sustained drug release properties and implantability advantages for local glioma chemotherapy.
Paclitaxel-loaded PLGA microspheres were fabricated using electrohydrodynamic atomization and entrapped by electrospray and gelation. The physicochemical characterizations were performed using scanning electron microscopy and differential scanning calorimetry. The influence of various parameters on the disintegration time was investigated. In vitro release of paclitaxel was quantified using high performance liquid chromatography. Cytotoxicity of the formulations was assessed by the quantification of IC(50) and caspase-3 activity against C6 glioma cells in vitro. The formulations were tested against a subcutaneous C6 glioma tumour in mice.
Highly monodisperse gel beads containing a uniform microsphere distribution were obtained. Gelation using Ca(2+) ions ensured entrapment of microspheres with high loading efficiency. With an increase in the gelation time, gelling bath concentration and decrease in microsphere loading, it was more difficult to disintegrate the beads and release the microspheres. The formulations demonstrated sustained drug release for more than 60 days at a near-constant rate and a low initial burst. Cell culture studies proved the cytotoxicity against C6 glioma and improved performance in comparison to Taxol. The formulations could reduce subcutaneous tumour volume to a greater extent compared to Taxol and the control.
Paclitaxel-loaded PLGA microspheres entrapped in an alginate gel matrix could be potential local chemotherapy implants to treat malignant glioma with critical advantages of implantability and sustained drug release with low initial burst.
制备包裹于凝胶基质中的载紫杉醇聚乳酸-羟基乙酸共聚物(PLGA)微球,使其具有药物缓释特性及可植入性优势,用于局部胶质瘤化疗。
采用电液动力雾化法制备载紫杉醇的PLGA微球,并通过电喷雾和凝胶化将其包裹。使用扫描电子显微镜和差示扫描量热法进行理化特性表征。研究了各种参数对崩解时间的影响。采用高效液相色谱法定量测定紫杉醇的体外释放。通过定量IC(50)和体外针对C6胶质瘤细胞的半胱天冬酶-3活性评估制剂的细胞毒性。在小鼠皮下C6胶质瘤肿瘤模型上对制剂进行测试。
获得了高度单分散的凝胶珠,其中微球分布均匀。使用Ca(2+)离子进行凝胶化可确保微球的高负载效率包封。随着凝胶化时间的增加、凝胶浴浓度的增加以及微球负载量的减少,珠子崩解和微球释放变得更加困难。制剂在近恒定速率下持续释放药物超过60天,且初始突释较低。细胞培养研究证明了其对C6胶质瘤的细胞毒性,并与紫杉醇相比具有更好的性能。与紫杉醇和对照组相比,制剂可更大程度地减小皮下肿瘤体积。
包裹于藻酸盐凝胶基质中的载紫杉醇PLGA微球可能是治疗恶性胶质瘤的潜在局部化疗植入物,具有可植入性和低初始突释的持续药物释放的关键优势。